INO - Inovio Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.11 (+0.47%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close23.27
Bid23.25 x 1100
Ask23.28 x 1400
Day's Range22.65 - 23.60
52 Week Range1.92 - 33.79
Avg. Volume42,105,795
Market Cap3.696B
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-1.16
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Could Buying Inovio Pharmaceuticals Stock Make You Rich?
    Motley Fool

    Could Buying Inovio Pharmaceuticals Stock Make You Rich?

    Over the five-year period leading up to 2020, Inovio Pharmaceuticals (NASDAQ: INO) delivered a positive return in just one year: In 2016, Inovio gained a little over 3%. The company has emerged as one of a handful of small drugmakers with promising COVID-19 vaccine candidates. Could buying Inovio stock now make you rich over the next several years?

  • Coronavirus Vaccine Race: Moderna or Inovio?
    Motley Fool

    Coronavirus Vaccine Race: Moderna or Inovio?

    Multiple drugmakers are scrambling to develop COVID-19 vaccine candidates. In terms of clinical progress, Moderna (NASDAQ: MRNA) appears to be neck-and-neck for the lead with a partnership between AstraZeneca and the University of Oxford. The U.S. biotech hopes to begin a pivotal late-stage study of its COVID-19 vaccine candidate mRNA-1273 later this month.

  • INO Stock Could Receive Operation Warp Speed Funding Soon

    INO Stock Could Receive Operation Warp Speed Funding Soon

    Will Inovio (NASDAQ:INO) and INO stock explode, or is its run over? Creating vaccines requires massive resources. Thus, questions regarding the ability of smaller biotech companies to compete with their better-heeled and more experienced adversaries have persisted. Yet, the potential return on smaller biotech companies was and perhaps remains too tempting.Source: Ascannio / Reports that government scientists are having trouble running trials with Moderna (NASDAQ:MRNA) don't bode well for smaller biotech companies pursuing a vaccine. That much larger drug makers like Johnson & Johnson (NYSE:JNJ) have not received such complaints is telling. This points to the sophistication and advanced nature of the large drug makers' Covid-19 programs. Perhaps they are simply better versed in cooperating with the government. Nevertheless, investors should recognize the risk these smaller biotech stocks represent. Inovio may yet receive government funding and explode.InvestorPlace - Stock Market News, Stock Advice & Trading Tips A Reversal of Fortune at Inovio?Barron's reports a reversal of analyst sentiment regarding Inovio within the past month. One month ago the tally was five "buys," three "holds", and no "sells." Consensus was that the stock was overweight at that time. However, the current tally is two "buys," five "holds," and one "sell" with the consensus being to hold it. * The 7 Best Stocks to Invest in Right Now Investors should bear this change of sentiment in mind given recent news concerning Novavax (NASDAQ:NVAX) and Regeneron (NASDAQ:REGN). The federal government signed a $450 million contract with Regeneron to purchase as many as 1.3 million does of its antibody cocktail. Novavax announced that it received $1.6 billion to test its Covid-19 vaccine. Novavax does not have any commercially marketed products and yet it is receiving $1.6 billion in funding. Markets should interpret this as one of two things: either the government is hedging a massive bet, or it knows more about Novavax's vaccine than has been released. Given that Novavax shares popped 29% following the funding news, markets are betting on the latter. Inovio Seeking Government CooperationInovio's ability to leverage government relationships in the fight against the pandemic is crucial. It seeks to do what Novavax and Regeron have recently achieved. Former U.S. military vaccine and pandemic expert Dr. Mammen Mammen joined Inovio on June 25 to lead clinical development of the vaccine. Two days prior, Inovo received $71 million in funding to scale up manufacturing of its vaccine delivery device. Inovio's CELLECTRA 3PSP proprietary delivery device delivers INO-4800 directly into the skin. Investors are keenly scrutinizing these developments and their potential.Markets also want to know when peer review news will be released relating to INO-4800. This will be very important on the heels of the news released on June 30. Inovio's June 30 press release regarding phase 1 data for their INO-4800 vaccine didn't spike the price. Market reactions indicated some skepticism regarding Inovio's claims about INO-4800. Thus, investors will await peer review for the drug, which will likely serve to confirm or discredit the company-issued June 30 statement. Inovio also stated that it will begin a 2-stage trial in Korea. Inovio announced it added Gene Kim to its management team. He has a long history of leading Korean biotechs and previously helped list an IPO. INO Shares Might Rise to Warp SpeedThe federal government's largest expenditure in Operation Warp Speed thus far has been its bet on Novavax. The government's $1.6 billion bet is a clear indication that unproven biotech companies are a pillar of its Covid-19 strategy. Signs certainly point to a possible Operation Warp Speed funding announcement of Inovio in the coming weeks. Despite the market's tepid reception of Inovio's June news, there are signs of something big coming. The company is scrambling and aligning a coherent strategy in this volatile environment. Investors can also assume that a government funding deal is being discussed. Is INO Stock a Buy?INO stock is absolutely a hold and given all of the signs, one to consider as a Covid-19 play. Inovio has huge upside. The more I read about this stock the more I feel like investors are going to only regret not buying it. However, this is all speculation. Inovio could certainly strike out in regards to INO-4800. The company, however, has many other products in its pipeline and I can't help but feel like it's headed somewhere positive. As of writing, Alex Sirois does not own any of the aforementioned stocks. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post INO Stock Could Receive Operation Warp Speed Funding Soon appeared first on InvestorPlace.

  • 3 Reasons to Invest in, Not Trade iBio

    3 Reasons to Invest in, Not Trade iBio

    Stuck in a "soft" quarantine, I turned to what most people did during the hard quarantine - watch the film Contagion. It's been quite a while since I last saw the terrifying depiction of a devastating pandemic. After giving it another run through, I'm struck at how ominously accurate the movie is regarding the novel coronavirus. And this brings me to iBio (NYSEAMERICAN:IBIO) and specifically, IBIO stock.Source: Shutterstock Over the last few months that I covered this biotechnology firm, I described its equity as a speculative opportunity to advantage with "dumb" money. In other words, as a pure gamble, you could do a lot worse. Should the organization live up to its claim of mass-production of a coronavirus vaccine, IBIO stock could veritably skyrocket.But as shares have steadily ticked higher since early April and as demand for a vaccine consistently rises, I'm willing to sharpen my prognostication for iBio. Rather than it being a dumb money move, it's a rational one.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDon't get me wrong - IBIO stock is still ultra-risky. However, what has given me more confidence in the underlying company is that a return to normalcy may be impossible without a biological solution to this crisis.In carefully watching Contagion, I realized what made this narrative so compelling from a filmmaking perspective is plot organization. Starting with the initial strike, the protagonists work through the fictional MEV-1 virus' second wave, which then culminates in a vaccine and its unwieldy distribution. * The 7 Best Stocks to Invest in Right Now Each segment in the film features its own conflict. What intrigued me about Contagion's final act was that the mere production of a vaccine wasn't enough. This brings me to my first of three bullish factors for iBio. Scale Is the Distinguisher for IBIO StockAs the New York Times spelled out a few months ago, several entities are developing a novel coronavirus vaccine. Contrary to some people's opinions, this development process is long, arduous and expensive. It's not as easy as injecting disinfectants.Therefore, you're looking at a two-front battle. First, a pharmaceutical company must forward a truly viable and effective vaccine. Second, it's got to bring that vaccine to scale so that the entire nation can benefit. Both challenges will be difficult to overcome.But as I pointed out in early June, scale is what distinguishes IBIO stock from the competition. I wrote:The driving force behind the company is a proprietary technology called the FastPharming Manufacturing System. Using a relative to the tobacco plant as a "bioreactor," iBio can theoretically take a vaccine and scale it up to necessary commercial volume. According to iBio co-chairman and CEO Tom Isett, the firm can "make about 500 million doses of high-quality product annually."Granted, the company must live up to its claims. Otherwise, it can go downhill quickly for IBIO stock. Nevertheless, if it can achieve this scale, the U.S. government's ambitious target to get a vaccine within a 12- to 18-month window is much more credible. Multiple Paths to SuccessAnother previously not well known pharmaceutical company in the coronavirus vaccine race is Inovio Pharmaceuticals (NASDAQ:INO). Despite question marks over its candidate's viability, INO shares are still performing outstandingly. In part, this may be because there are multiple paths to success.According to Dr. James Samuel, a regents' professor and the head of the Department of Microbial Pathogenesis and Immunology at the Texas A&M University College of Medicine, initial coronavirus vaccines may be helpful for healthy individuals. However, Dr. Samuel cautioned that other vaccines may need to be developed for medically vulnerable individuals.As Dr. Samuel put it, "The challenge is a lot more complicated than a single vaccine… The scale of the problem alone is unprecedented. This will not be a horse race with a single winner."Therefore, just because a company beats everyone else to an effective vaccine doesn't spell disaster for others. First, scaling up that vaccine is a challenge, but one that would better suit iBio. Second, multiple vaccines may be necessary to fully address the Covid-19 pandemic.So, IBIO stock may have a safety margin that some investors may not be aware of. Economic Demand Is SurgingWhoever forwards genuine solutions, investors of that organization will find themselves loving life (assuming they don't get Covid-19 and die). But the financial implications of a vaccine don't just end on Wall Street. Indeed, the domestic and perhaps the international economy is dependent on it.For the most part, Americans have graciously adopted previously foreign practices, such as wearing masks and practicing social distancing. But skyrocketing new daily coronavirus cases, along with an uptick in Covid-19-related deaths have cast a shadow on these measures' efficacy.If only from the power of perception, the U.S. desperately needs a vaccine. It's much easier to convince businesses to reopen and people to spend if we have a substantive, meaningful solution.This also means that there's extra leeway in terms of the vaccine development process. Stated differently, a less-than-desirable result may not spell immediate red ink for pharmaceutical players. And that adds another measure of confidence toward IBIO stock.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post 3 Reasons to Invest in, Not Trade iBio appeared first on InvestorPlace.

  • Inovio Subcontractor Hits Back With Lawsuit Against Coronavirus Vaccine Developer

    Inovio Subcontractor Hits Back With Lawsuit Against Coronavirus Vaccine Developer

    Inovio Pharmaceuticals Inc (NASDAQ: INO) could be embroiled in a prolonged legal battle with its Blue Bell, Pennsylvania-headquartered subcontractor VGXI, Inc, after the subcontractor sued the pharma company. The Inovio Lawsuit: VGXI filed a lawsuit this week in the Montgomery County Court of Common Pleas, with the plaintiff accusing Inovio of breach of contract, unfair competition, misappropriation of trade secrets and unjust enrichment, the Philadelphia Business Journal reported.Inovio initiated legal proceedings against VGXI, a subsidiary of South Korea's GeneOne Life Sciences, in early June, accusing it of not transferring technical know-how to manufacture doses of INO-4800, Inovio's DNA vaccine candidate against SARS-CoV-2.Inovio's contention was that VGXI did not possess the wherewithal to scale up manufacturing, which is essential for getting regulatory clearance.In late June, the Montgomery County Court denied Inovio's request for an injunction against VGXI."Inovio got greedy. It saw the opportunity to reap vast riches and keep its stock price soaring if it could win the race to a COVID-19 vaccine, but Inovio did not want to pay VGXI for the manufacturing," VGXI reportedly said in the lawsuit.Inovio chose to unfairly take possession of VGXI's proprietary technology and manufacturing processes and pass on to as many as 10 other manufacturers around the world, including in China and India, the lawsuit alleges. What's Next For Inovio: The lawsuit from VGXI will not impact Inovio's coronavirus vaccine development, an Inovio spokesman told Benzinga in an email Friday. "If we have an effective vaccine, manufacturing will not be an issue," he said, adding that the Phase 2/3 trail for INO-4800 is on track to begin this summer.Inovio reported June 30 with interim results from a Phase 1 study of INO-4800, which showed that 94% of Phase 1 trial participants demonstrated immune responses at week six after two doses of INO-4800.The company also announced it has been selected to take part in a non-human primate challenge study under the federal government's Operation Warp Speed..Inovio shares were down 0.67% at $23.12 at last check.Related Links:Revisiting Coronavirus Vaccine Timelines: Moderna Denies Delay, Pfizer Advances Project Lightspeed And More Moderna Analyst Says Biotech Has 'First-To-Market' Potential For Coronavirus Vaccine See more from Benzinga * The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus * Inovio Plunges On Interim Phase 1 Coronavirus Data; DNA Vaccine Shows 94% Response Rate(C) 2020 Benzinga does not provide investment advice. All rights reserved.

  • In the Race to a Coronavirus Vaccine, Buy Moderna Stock or Inovio Stock?
    Motley Fool

    In the Race to a Coronavirus Vaccine, Buy Moderna Stock or Inovio Stock?

    Shares of potential COVID-19 developers have surged with each bit of news. But one offers better prospects for investors.

  • Covid-19 Research Update: The Stars and the Question Marks

    Covid-19 Research Update: The Stars and the Question Marks

    While giants like Gilead Sciences and Pfizer are progressing well, many small players have witnessed setbacks in their Covid-19 research Continue reading...

  • Where COVID-19 vaccine trials stand
    Yahoo Finance Video

    Where COVID-19 vaccine trials stand

    Dr. Fauci says he expects phase 3 vaccine trials to begin at the end of July. Yahoo Finance's Anjalee Khemlani joins the On the Move panel to discuss where vaccine trials stand.

  • 3 Things Inovio Stock Bulls Need to Happen Soon
    Motley Fool

    3 Things Inovio Stock Bulls Need to Happen Soon

    With so many companies trying to solve the coronavirus problem, now's a critical time for the biotech stock.

  • Is There a Coronavirus Vaccine Yet?
    Motley Fool

    Is There a Coronavirus Vaccine Yet?

    Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp speed.”

  • Why Inovio Stock Soared 83% in June
    Motley Fool

    Why Inovio Stock Soared 83% in June

    What happened Inovio Pharmaceuticals (NASDAQ: INO) stock skyrocketed 82.7% in June, according to data from S&P Global Market Intelligence. The S&P 500 returned 2% last month. In July, shares of the coronavirus vaccine developer, however, have given back a chunk of last month's gain: Through Tuesday, July 7, they're down nearly 11%, while the broader market has returned just over 3%.

  • Fauci warns that COVID-19 vaccine protection may be ‘finite’

    Fauci warns that COVID-19 vaccine protection may be ‘finite’

    Speaking at a live-streamed videoconference hosted by the National Institutes of Health, Dr. Anthony Fauci, White House coronavirus task force member and director of the National Institute of Allergy and Infectious Diseases, said it is difficult to tell how long a vaccine will work.

  • Analyst Sounds the Valuation Alarm Bell on Inovio’s Hot Stock

    Analyst Sounds the Valuation Alarm Bell on Inovio’s Hot Stock

    And just like that, the tides have turned for Inovio Pharmaceuticals (INO). Shares of the high-flying biotech dropped last week by 31%, the vast majority of which came after the release of interim data from the early stage trial of its COVID-19 vaccine candidate, INO-4800.You could chalk the dip up to a classic case of “buy the rumor, sell the news,” but this sell-off was slightly more nuanced, with the lack of a clear good/bad story leaving a lot to interpretation.The company said that after giving participants two doses of the vaccine, 94% "demonstrated overall immune responses." What probably concerned investors was the fact that finer immune response details were missing. Specifically, how many patients produced neutralizing antibodies that could prevent a COVID-19 infection. This looks bad when compared to Pfizer/BioNTech, as they published a richly detailed report of their candidate’s progress on the same day.The full data is expected to be published in a medical journal in the near future. Meanwhile, at investment firm Maxim, analyst Naureen Quibria believes the data was “positive.”The analyst said, “In truth, while we don’t know what 'good' immunogenicity data should be, studies suggest that both T cell and antibody immune responses will be important for protection in both mild and serious infections, particularly given that most convalescent plasmas obtained from individuals that have recovered from COVID-19 do not appear to contain high levels of neutralizing activity (e.g., one study, published in Nature). However, reports have also highlighted that the virus-specific T cells found in convalescent patients can control the severity of their COVID-19 disease. As such, the early data for INO-4800 appear to be promising, in our view.”However, the analyst can’t ignore Inovio’s lofty valuation, which, along with the murky data, played a part in the sell-off. Even after last week’s drop, shares are still up by 540% since the turn of the year. Therefore, for Quibria, “the success of INO-4800 is priced into the shares.”Accordingly, Quibria downgraded Inovio from Buy to Hold, and took the price target off the table. (To watch Quibria’s track record, click here)Other analysts appear to be reading from the same page. Based on 2 Buys, 5 Holds and 1 Sell, Inovio has a Hold consensus rating. There’s small upside of 3% in the cards, should the average price target of $22 be met over the next 12 months. (See Inovio stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • After months of speculation, investors get excited about Pfizer, BioNTech’s coronavirus vaccine candidate

    After months of speculation, investors get excited about Pfizer, BioNTech’s coronavirus vaccine candidate

    The path to a COVID-19 vaccine has started to come into view this week, following the stock-moving disclosures of preliminary clinical data for two candidates and a rigorous new regulatory road map from the Food and Drug Administration.

  • Inovio Stock: Buy, Sell, or Hold?
    Motley Fool

    Inovio Stock: Buy, Sell, or Hold?

    Inovio Pharmaceuticals (NASDAQ: INO) has been grabbing a lot of headlines over the past few weeks, mostly thanks to its involvement in the race to find a vaccine for COVID-19. The company claimed to have come up with its potential vaccine, INO-4800, in a mere three hours after Chinese researchers publicly published the genetic sequence of the SARS-CoV-2 virus that causes COVID-19. Inovio initiated a phase 1 clinical trial for this vaccine in early April.

  • Why Inovio Pharmaceuticals Stock Is Bouncing Back Today
    Motley Fool

    Why Inovio Pharmaceuticals Stock Is Bouncing Back Today

    Shares of Inovio Pharmaceuticals (NASDAQ: INO) were bouncing back on Thursday after being clobbered earlier this week. The biotech stock still has a long way to go to make up its lost ground. Inovio's shares were down 37% this week as of the close on Wednesday.

  • 3 Reasons Moderna Is a Better Coronavirus Stock Than Inovio
    Motley Fool

    3 Reasons Moderna Is a Better Coronavirus Stock Than Inovio

    If you only looked at stock performance, you might conclude that Inovio Pharmaceuticals (NASDAQ: INO) is a better coronavirus stock than Moderna (NASDAQ: MRNA). While Moderna's share price has more than tripled so far in 2020, Inovio stock has skyrocketed more than 700%. There's a strong case to be made that Moderna is actually the better pick of these two coronavirus-focused biotech stocks.

  • MarketWatch

    Maxim downgrades Inovio, saying coronavirus opportunity is already 'priced in'

    Shares of Inovio Pharmaceuticals Inc. declined 15.3% in trading on Wednesday after Maxim Group downgraded the stock to hold from buy. Inovio, which is developing a COVID-19 vaccine, had announced some limited, clinical data about how the candidate performed in a Phase 1 trial on Tuesday. Maxim analysts said it appears that the COVID-19 "opportunity" is already baked into the valuation as shares of Inovio have soared 593.0% year-to-date. "In our opinion, the success of INO-4800 is priced into the shares," they wrote in a note to investors on Wednesday. The company's stock hit a record high of $31.69 on Monday, the day before it released the positive, yet limited data about its vaccine candidate. Inovio said that the full trial data will be published in a peer-reviewed medical journal. The stock then tumbled after it shared the data on Tuesday, closing at $26.95. The S&P 500 is down 4.0% year-to-date.

  • Has Inovio Stock Surged Enough for Now? This Analyst Says Yes

    Has Inovio Stock Surged Enough for Now? This Analyst Says Yes

    The frantic global search for a vaccine or therapy for the coronavirus has sent the valuations of previously small cap biotechs to unimagined heights over a short period of time. There can’t be many better examples for the phenomenon than Inovio Pharmaceuticals (INO). Investors have cheered the progress of its COVID-19 DNA vaccine candidate INO-4800 by sending shares on a mightily impressive run – the stock is up by 505% since the turn of the year (even after today's 25% sell off).The massive gains, the richly valued $3.2 billion market cap and a track record that – while promising – has yet to yield any significant results have prompted a rethink at investment firm H.C. Wainwright.“We believe the risk/reward ratio for Inovio has increased significantly as many open questions remain,” said firm analyst Ram Selvaraju, “Including the strength and duration of neutralizing antibodies and T cell responses that may be generated in human trials and the effective protection the vaccine may demonstrate in animal challenge studies.” “As a reminder,” concluded the 5-star analyst, “There is no approved human vaccine for any type of coronavirus, while no DNA vaccines have been approved for human use yet.”INO-4800 is currently in a Phase 1 trial with interim data expected any day now. A Phase 2/3 trial of INO-4800 is also planned to go ahead this summer. The company will need to demonstrate why its DNA based approach is “superior.” Proof Inovio can run the gamut from market authorization, to maintaining enough supply to pricing the vaccine reasonably while also driving profit, will also be required. Lastly, Selveraju says, Inovio’s offering will need to show “evidence that the immunity afforded by vaccination lasts sufficiently to have a significant impact on the spread of the coronavirus pandemic.”As these questions remain to be answered, Selvaraju slashed his rating on INO from Buy to Neutral, while removing his price target. (To watch Selvaraju’s track record, click here)Selveraju’s view is partially echoed by his colleagues across the Street, with 5 analysts saying Hold, and 3 suggesting Buy. Yet, the average price target of $26.50 implies 31% upside from current levels. (See Inovio stock-price forecast on TipRanks)To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Coronavirus update: Pfizer spurs new hope in vaccine race as NYC pulls back on dining plans
    Yahoo Finance

    Coronavirus update: Pfizer spurs new hope in vaccine race as NYC pulls back on dining plans

    Pfizer (PFE) on Wednesday announced early positive results for the first phase of its coronavirus vaccine trial, sparking hopes that an effective treatment can help turn the tide amid an implacable surge in new infections.

  • Why Inovio Pharmaceuticals Stock Is Crashing Today
    Motley Fool

    Why Inovio Pharmaceuticals Stock Is Crashing Today

    Lingering disappointment over results announced on Tuesday and an FDA update are weighing on the stock.


    New FDA Guidance May Not Allow Covid-19 Vaccine This Year, Analyst Says

    The Food and Drug Administration’s new guidance document for developers of Covid-19 vaccines doesn’t spell out a timeline. SVB Leerink analyst Geoffrey Porges says the guidelines point firmly toward no vaccine being made available until next year.

  • Inovio's Manufacturing, Scalability Concerns Of Coronavirus Vaccine Keeps This Analyst On The Sidelines

    Inovio's Manufacturing, Scalability Concerns Of Coronavirus Vaccine Keeps This Analyst On The Sidelines

    Inovio Pharmaceuticals Inc (NASDAQ: INO) reported Tuesday interim Phase 1 readout for INO-4800, its DNA vaccine candidate against the novel coronavirus.The Inovio Analyst: Piper Sandler analyst Christopher Raymond maintained a Neutral rating and $8 price target for Inovio.The Inovio Thesis: There wasn't a ton of detail at this point from the readout except that 94% or 34 of the 36 patients, demonstrating an "overall immunological" response at week 6, with a benign safety profile, Raymond said in a note. This appeared consistent with preclinical data published in May.Raymond, however, said he would like to see data on neutralizing antibody production and T cell response generation separately and broken out by dose before drawing too many conclusions.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.The analyst expressed satisfaction with the safety data reported by Inovio."While initial human immunogenicity data is a necessary first step toward a viable COVID-19 vaccine, at this stage it's difficult (if not impossible) to determine which development candidate(s) will fare best in large-scale clinical trials," Raymond wrote in the note.An equally important consideration is scalability.The analyst is concerned over Inovio's dispute with its longtime manufacturing partner VGXI.Investor hopes for INO-4800 to emerge as a viable vaccine candidate to address the current COVID-19 pandemic could prove unrealistic, barring clarity on the manufacturing scalability front, the analyst said.Inovio Price Action: Inovio shares tumbled 14.9% to $26.95.Latest Ratings for INO DateFirmActionFromTo Jun 2020HC Wainwright & Co.DowngradesBuyNeutral Jun 2020Cantor FitzgeraldMaintainsOverweight Jun 2020StifelDowngradesBuyHold View More Analyst Ratings for INO View the Latest Analyst Ratings See more from Benzinga * Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally * The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week(C) 2020 Benzinga does not provide investment advice. All rights reserved.

  • Why Inovio Pharmaceuticals Plunged 20% Today

    Why Inovio Pharmaceuticals Plunged 20% Today

    Shares of biotech company Inovio Pharmaceuticals (INO) fell sharply on Tuesday after announcing updates to its Covid-19 vaccine candidate, INO-4800.